Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of
oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients
with motor fluctuations.